Therapeutic vaccines in solid tumours: can they be harmful?
about
Update on the challenges and recent advances in cancer immunotherapyIn vivo imaging of therapy-induced anti-cancer immune responses in humans.NGcGM3 ganglioside: a privileged target for cancer vaccinesRepeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.Microbiota modulation of myeloid cells in cancer therapyCancer vaccines and carbohydrate epitopes.Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancerMultiple vaccinations: friend or foe.Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.Unravelling the complexity of cancer-immune system interplay.Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Carbohydrate-based cancer vaccines: target cancer with sugar bullets.Evolving role of tumor antigens for future melanoma therapies.Adjuvant therapy for high-risk melanomaThe Human Vaccines Project: A roadmap for cancer vaccine development.Microbiota: a key orchestrator of cancer therapy.Overall survival and PD-L1 expression in metastasized malignant melanoma.Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.In vitro and in vivo antitumor effects of 50 to 100-KDa components from B16 melanoma culture supernatant."First do no harm" and the importance of prediction in oncology.Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer.Vaccination of patients with cutaneous melanoma with telomerase-specific peptides.
P2860
Q27014693-D168A264-AFE0-4A0D-9069-4196662EF70CQ27693338-332D6EA3-254B-4470-BEB6-C84CF84F2575Q34247856-68B4040D-36BE-4B35-86CE-CCDEC8ECF147Q34612637-20B7E499-8158-4B8D-A98B-A3237CAB4171Q35073092-E70EF6A8-9A0E-4654-B945-62C14D253E5BQ35525289-9EDC1F7E-5E93-4236-BFEA-53D0650C02B0Q36631314-725D60DC-DD2E-431F-8041-02C287C7B1FDQ36734688-9003EDF7-398D-4F56-A89B-A06EA3BDAEF9Q37442739-1620AC8A-1E41-45B4-933D-3010F37D45CBQ37762274-4CD81A53-3E7C-461B-854B-29FBFB65F5B6Q37765590-93C33C7C-627F-4337-B92A-58F4B94EB547Q37809856-C4501188-3A1B-44CE-AF51-737A67678A66Q37952804-DABD0178-8274-494F-B3DF-71736E1BFB2DQ38016342-EBD12BD0-B352-4ED9-872D-AAAA915B261FQ38232855-4C079B00-BFFE-4FB3-8BD8-0F0BC2033AB2Q38555842-CB443537-AC88-4125-A476-84989F487555Q38807692-AD1A65C4-0AAF-45B0-9B23-687A08F4FEE7Q39183428-F6DA11EB-1425-4506-8798-6F81B14F8BBEQ39756798-D725118C-8696-4B20-BF39-185055E71768Q41073960-CDBF1BA1-2A55-4A1F-8EEF-84783C997545Q41550106-9D72749A-0C90-41DF-8FA4-824236BC07DAQ41731147-296C5143-70B6-42C7-900B-B9FDACAA4700Q43897776-2D8BAC3D-302C-469E-8654-15C47EF9D5B2Q54580812-B8EFACF9-9985-4BF0-A2B3-5888F57D7A60
P2860
Therapeutic vaccines in solid tumours: can they be harmful?
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Therapeutic vaccines in solid tumours: can they be harmful?
@ast
Therapeutic vaccines in solid tumours: can they be harmful?
@en
type
label
Therapeutic vaccines in solid tumours: can they be harmful?
@ast
Therapeutic vaccines in solid tumours: can they be harmful?
@en
prefLabel
Therapeutic vaccines in solid tumours: can they be harmful?
@ast
Therapeutic vaccines in solid tumours: can they be harmful?
@en
P1476
Therapeutic vaccines in solid tumours: can they be harmful?
@en
P2093
Alexander M M Eggermont
P304
P356
10.1016/J.EJCA.2009.05.004
P577
2009-05-22T00:00:00Z